Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$42.77M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
1540.32%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$24.01M
Q3 2024
Cash
Q3 2024
P/E
-2.307
Nov 29, 2024 EST
Free Cash Flow
-$22.91M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $1.000M $5.000M $15.00M $0.00 $0.00 $0.00 $0.00
YoY Change -80.0% -66.67%

Expenses

Cost Of Revenues

No data

Gross Profit

No data

Gross Profit Margin

No data

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017
Revenue $1.000M $5.000M $15.00M $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

No data

R&D To Gross Profit Ratio

No data

DDA To Gross Profit Ratio

No data

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017
Selling, General & Admin $31.05M $24.81M $19.40M $16.22M $15.90M $6.970M $2.630M
YoY Change 25.12% 27.89% 19.62% 2.01% 128.12% 165.02%
% of Gross Profit
Research & Development $31.05M $39.83M $38.67M $34.49M $41.99M $16.85M $5.640M
YoY Change -22.04% 2.99% 12.13% -17.87% 149.2% 198.76%
% of Gross Profit
Depreciation & Amortization $92.00K $89.00K $93.00K $97.00K $40.00K $10.00K $10.00K
YoY Change 3.37% -4.3% -4.12% 142.5% 300.0% 0.0%
% of Gross Profit
Operating Expenses $31.05M $39.83M $38.67M $34.49M $57.88M $23.82M $8.270M
YoY Change -22.04% 2.99% 12.13% -40.41% 142.99% 188.03%
Operating Profit -$61.10M -$59.64M -$43.07M -$50.71M
YoY Change 2.44% 38.47% -15.06%

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

No data

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017
Interest Expense $2.554M $1.254M $220.0K $730.0K $2.600M $710.0K $190.0K
YoY Change 103.67% 470.0% -69.86% -71.92% 266.2% 273.68%
% of Operating Profit
Other Income/Expense, Net
YoY Change

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017
Pretax Income -$59.69M -$58.39M -$42.85M -$49.98M -$55.29M -$23.11M -$8.080M
YoY Change 2.22% 36.25% -14.27% -9.6% 139.25% 186.01%
Income Tax $0.00 -$17.00K -$60.00K $70.00K $0.00
% Of Pretax Income
Net Earnings -$59.69M -$58.39M -$42.85M -$49.97M -$55.23M -$23.19M -$8.090M
YoY Change 2.22% 36.25% -14.24% -9.53% 138.16% 186.65%
Net Earnings / Revenue -5968.5% -1167.76% -285.69%
Basic Earnings Per Share -$1.39 -$1.38 -$1.02 -$1.70
Diluted Earnings Per Share -$1.39 -$1.38 -$1.02 -$1.70 -$3.500M -$980.5K -$342.1K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

No data

Receivables

No data

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

No data

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

No data

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017
Cash & Short-Term Investments $66.00M $64.58M $114.1M $142.3M $119.8M $86.00M $26.90M
YoY Change 2.2% -43.42% -19.79% 18.78% 39.3% 219.7%
Cash & Equivalents $13.76M $7.636M $114.1M $72.30M $119.8M $85.90M $10.90M
Short-Term Investments $52.24M $56.95M $0.00 $70.00M $0.00 $0.00 $16.00M
Other Short-Term Assets $3.178M $6.005M $4.299M $5.400M $1.800M $1.400M $100.0K
YoY Change -47.08% 39.68% -20.39% 200.0% 28.57% 1300.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $73.03M $71.80M $118.9M $148.7M $122.5M $88.10M $27.60M
YoY Change 1.71% -39.62% -20.02% 21.39% 39.05% 219.2%
Property, Plant & Equipment $2.194M $2.680M $926.0K $1.300M $900.0K $0.00 $0.00
YoY Change -18.13% 189.42% -28.77% 44.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $2.194M $2.680M $926.0K $1.300M $900.0K $0.00 $0.00
YoY Change -18.13% 189.42% -28.77% 44.44%
Total Assets $75.23M $74.48M $119.8M $150.0M $123.4M $88.10M $27.60M
YoY Change
Accounts Payable $3.981M $2.263M $4.384M $4.600M $4.400M $2.600M $800.0K
YoY Change 75.92% -48.38% -4.7% 4.55% 69.23% 225.0%
Accrued Expenses $3.245M $3.876M $2.391M $1.500M $4.000M $1.700M $600.0K
YoY Change -16.28% 62.11% 59.4% -62.5% 135.29% 183.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.226M $6.139M $6.775M $6.200M $8.300M $4.500M $1.600M
YoY Change 17.71% -9.39% 9.27% -25.3% 84.44% 181.25%
Long-Term Debt $49.77M $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.457M $1.996M $474.0K $700.0K $200.0K
YoY Change -27.0% 321.1% -32.29% 250.0%
Total Long-Term Liabilities $51.23M $1.996M $474.0K $700.0K $200.0K $0.00 $0.00
YoY Change 2466.58% 321.1% -32.29% 250.0%
Total Liabilities $58.46M $8.135M $7.249M $6.900M $8.500M $4.500M $1.600M
YoY Change 618.56% 12.22% 5.06% -18.82% 88.89% 181.25%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

No data

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017
Basic Shares Outstanding
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $98.657 Million

About Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 47 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.

Industry: Pharmaceutical Preparations Peers: Lexaria Bioscience Corp.